Leveraging MultiLINK™ Technology to Optimize ADC Selection & Improve the Therapeutic Window of ADCs - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Leveraging MultiLINK™ Technology to Optimize ADC Selection & Improve the Therapeutic Window of ADCs

12:30 pm - Tuesday 13th October 2026

Maximizing therapeutic impact against low expressing targets and rapidly proliferating tumors using targeted high DAR ADC architectures
Addressing current ADC challenges with novel linker-payloads: Preclinical proof-of-concept to preserve efficacy while enhancing ADC tolerability and therapeutic index
Detailing novel linker mechanism for safer sequential release of MMAE

Speakers:

Noemie Luong

Noemie Luong

Associate Principal Scientist, Translational Pharmacology

Debiopharm